Merck shares rose 2.8% in pre-open trading after the company reported a pair of late-stage clinical readouts that reinforced the commercial positioning of its pembrolizumab franchise.
The Phase 3 KEYNOTE-C93 trial of Keytruda as a single agent met its primary endpoint of progression-free survival in patients with mismatch repair deficient advanced or recurrent endometrial cancer, versus the standard carboplatin and paclitaxel chemotherapy regimen. At a pre-specified interim analysis, the study also showed a trend toward improvement in overall survival, providing additional context to the progression-free survival result.
Separately, the OptiTROP-Lung06 Phase 3 trial reported that sacituzumab tirumotecan - an antibody-drug conjugate developed by Kelun-Biotech targeting TROP2 - when administered in combination with Merck’s pembrolizumab, met its primary progression-free survival endpoint in PD-L1 negative non-small cell lung cancer patients. The trial was presented as the first global Phase 3 success in this difficult-to-treat PD-L1 negative population.
Analysts and market participants interpreted the pair of readouts as reinforcing Keytruda’s role as a foundational combination partner across multiple tumor types. BMO Capital raised its price target on Merck stock to $142 while keeping an Outperform rating, citing expectations for strong uptake of the subcutaneous Keytruda Qlex formulation after it received a permanent J-code for reimbursement.
The broader U.S. equity market provided a modestly supportive backdrop in pre-market trading, with the S&P 500 up 0.3%, the Dow Jones Industrial Average higher by 0.3%, and the Nasdaq rising 0.7%. While pharmaceutical peers such as Pfizer and Eli Lilly remain names to monitor, market observers noted that today’s move appeared to be driven largely by Merck-specific catalysts rather than sector-wide flows.
Merck’s Q2 2026 earnings report is scheduled for August 4. Investors appear to be digesting the string of positive pipeline developments as they reassess the near-term growth trajectory of the Keytruda franchise, even as longer-term patent considerations remain an overhang for the company.
Summary
Two Phase 3 readouts - KEYNOTE-C93 monotherapy success in mismatch repair deficient endometrial cancer and OptiTROP-Lung06 partner combination success in PD-L1 negative non-small cell lung cancer - helped lift Merck stock in pre-market trading, supported by an analyst upgrade and a mildly positive U.S. market tone ahead of Merck’s Q2 2026 results.
Key points
- Clinical wins bolster the commercial case for pembrolizumab as a combination partner across cancer types - impacting oncology and pharmaceutical sectors.
- BMO Capital raised its price target to $142 and maintained an Outperform rating, citing anticipated uptake of the subcutaneous Keytruda Qlex following a permanent J-code for reimbursement - relevant to healthcare services and reimbursement dynamics.
- Modest positive momentum in U.S. equity indices provided a supportive market backdrop, though the move was driven mainly by Merck-specific news.
Risks and uncertainties
- Longer-term patent expiry concerns continue to weigh on Merck’s outlook - a risk for the company and the broader pharmaceutical sector.
- Investor sentiment could shift ahead of Merck’s Q2 2026 earnings report on August 4 if forthcoming financials or guidance do not align with expectations - affecting equity markets and healthcare stocks.
- Although clinical readouts were positive for progression-free survival, the evidence on overall survival was described as a trend at interim analysis rather than a confirmed statistically significant result, leaving some clinical uncertainty.